{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-084309","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.770182+00:00","generated_at":"2026-05-15T22:41:15.553639+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intellia FDA lifts clinical hold on nex-z MAGNITUDE Phase 3 trial for ATTR-CM","bullets":["FDA removed clinical hold on MAGNITUDE Phase 3 trial of nex-z for ATTR-CM after Grade 4 liver event on Oct 29, 2025.","Mitigation measures include enhanced liver monitoring, short-term steroid guidance, and exclusion of certain liver abnormalities.","For MAGNITUDE, added exclusion criteria for recent cardiovascular instability and ejection fraction <25%.","MAGNITUDE-2 clinical hold for ATTRv-PN was resolved in January 2026; enrollment activities resuming.","Amended ATM offering to up to $1.035B aggregate (from $750M); $635M sold, up to $400M additional shares remain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-084309","json":"https://secwatch.observer/filing/0001193125-26-084309.json","markdown":"https://secwatch.observer/filing/0001193125-26-084309.md","text":"https://secwatch.observer/filing/0001193125-26-084309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/0001193125-26-084309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/d101756d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:41:15.553639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fe97d7a11f06887e48fd3eff142870e00cb9fea","claim":"Intellia Therapeutics, Inc. amended Sales Agreement with Jefferies LLC valued at $1,035,316,650 (effective 2026-03-02).","evidence_excerpt":"On March 2, 2026, the Company entered into an amendment to the Sales Agreement to increase the size of the at-the-market offering program from $750,000,000 to $1,035,316,650.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/0001193125-26-084309-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"$1,035,316,650"},{"label":"Effective","value":"2026-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}